

Year-end Report 2020

Webcast - February 19, 2021 at 10:00 am CET



Disclaimer

This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "Presentation"), has been prepared by Scandion Oncology A/S ("Scandion Oncology" or the "Company"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.

This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The Company has not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.


Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.

Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Past performance does not guarantee or predict future performance. Moreover, the Company does not – to the extent this is not required by law - undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.

This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Danish law. The courts of Denmark, with the District Court of Copenhagen as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.



Agenda



Key take-aways 2020



INITIATED TWO CLINICAL
TRIALS WITH OUR LEAD
COMPOUND SCO-101



STRENGTHENED AND
INTERNATIONALIZED
EXECUTIVE MANAGEMENT



SECURED FINANCING FOR
OUR TWO PLANNED EFFICACY
STUDIES WITH SCO-101



CHANGED LISTING FROM
SPOTLIGHT TO NASDAQ FIRST
NORTH GM, STOCKHOLM

Company Highlights from Q4 until present

Modified timelines CORIST and PANTAX

OCTOBER 7
Scandion Oncology announced modified timelines for the clinical Phase II colorectal cancer study (CORIST) and the Phase Ib study for pancreatic cancer (PANTAX)

Initiation of PANTAX Phase Ib

OCTOBER 28
Scandion Oncology announced that its second clinical study with SCO-101 had been initiated

Results from the Rights Issue

DECEMBER 15
Scandion Oncology announced the result of its Rights Issue, which provided the Company with proceeds amounting to approximately SEK 236 million before issue costs

Approval for trading on Nasdaq First North

JANUARY 19
Scandion Oncology announced that the Company had applied for and received approval for admission to trading on Nasdaq First North Growth Market Sweden

Completed first 12 patient cohort in CORIST

JANUARY 23
Scandion Oncology announced that the Company had completed the first 12 patient cohort in the ongoing dose-range finding part of the clinical Phase II study (CORIST)

Amendment to PANTAX study

JANUARY 28
Scandion Oncology announced that the Company had submitted an amendment to the Danish Medicines Agency regarding the PANTAX study. The amendment is based on the learnings obtained from treating the first 12 patients in the CORIST study

Clinical Pipeline



PROGRAM/ INDICATION	COMPOUND	PHASE	2020	2021	2022	2023
CORIST: Drug resistant metastatic colorectal cancer	SCO-101	Phase II part 1				
		Phase II part 2				
PANTAX: Inoperable or metastatic pancreatic cancer	SCO-101	Phase Ib				
		Phase II				
Biomarker development and clinical validation	SCO-101					

Highlights 2020

- **CORIST:** First patient received treatment on **May 27, 2020** (part 1 of Phase II study)
- **CORIST:** SCO-101 was demonstrated to potentiate the effect of chemotherapy in the first cohort of patients, **July 31, 2020**
- **PANTAX:** Phase Ib study initiated on **October 28, 2020**

Upcoming Key Events in 2021

- **CORIST:** Data read-out from part 1 (dose range finding) of Phase II is planned for **Q2, 2021**
- **CORIST:** Initiation of part 2 of Phase II is planned for **Q2, 2021**
- **PANTAX:** Data read-out from Phase Ib is planned for **Q3-Q4, 2021**



Financial Update 2020

Key Figures and Selected Financial Posts



Operating loss
Q4 2020

9.1 MDKK
(1.2 MDKK)

Operating loss
Q1 – Q4 2020

22.9 MDKK
(15.4 MDKK)

Earnings per share
Q1 – Q4 2020

-0.83 DKK/share
(-0.81 DKK/share)

Number of shares
December 31, 2020

32.1 million
(19.1 million)

Danish Company listed on Nasdaq First North GM

- Currency DKK (SCOL share traded in SEK)
- Danish Financial Statements Act
- Year-end report NOT audited


Results

- Operating loss 2020 is 22.9 MDKK
- Costs and losses are in line with plans and expectations
- Going concern statement is issued in annual report NOT quarterly report
- No commitments beyond what can be fulfilled


Shares

- Number of shares 32.1 million
- Numbers of shares increased by 13.1 million during 2020

Cash Position



Operating Expenses 2019 - 2020



Increased effort

Operating expenses and therefore cash burn will increase going forward due to

- Clinical studies CORIST and PANTAX
- Strengthening of organization



New listing on Nasdaq First North, Stockholm



The Cancer Drug Resistance Company

Expected Significant Events 2021




CORIST



Q2 2021

- Data read-out part 1 of Phase II study
- Initiate part 2 of Phase II study

Immuno-oncology



Q2 2021

- Read-out from the preclinical collaboration with Alligator Bioscience AB

PANTAX



Q3-Q4 2021

- Data read-out Phase Ib study
- Initiate application for randomized Phase II study

Financing
secured until at
least after 2022

Investment Highlights



Targeting cancer drug resistance

rapid peak sales can be reached given a combination therapy application

Scandion Oncology A/S is a clinical Phase II biotechnology company developing **first-in-class, oral, add-on drugs to revert resistance to existing anti-cancer therapies.**

Targeting USD 37bn chemotherapy market growing at 12% annually

Well-documented mechanisms of action

enabling the company to target a wide variety of cancer indications

Lead candidate, SCO-101, currently in clinical Phase II trial (CORIST) targeting metastatic chemotherapy resistant colorectal cancer. Data read-out from part 1 in Q2 2021

A Phase Ib trial (PANTAX) targeting metastatic pancreatic cancer was initiated in Q4 2020

Management and Board of Directors

track record of successfully developing biotechnology companies

Proven track-record of preclinical research, clinical trials and deal activities paves the way for **future commercial success whilst reducing execution risk**



Q&A

Investor Relations:

Bo Rode Hansen, President & CEO

Email: ir@scandiononcology.com

Phone: +45 38 10 20 17

**Sign up to Scandion news on
our website:**

www.scandiononcology.com



The Cancer Drug Resistance Company